LNSRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
LENSAR, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.75−0.05 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $132.41M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.10 (−51.48%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
LENSAR, Inc. grew revenue 3.3% to $60.26M over the twelve months to Jun 30, 2026. Free cash flow was -$14.91M.
Revenue
$60.26M
+3.3% vs. a year earlier
Operating income
-$8.13M
TTM Q2 2026
Free cash flow
-$14.91M
FY2025
EPS, diluted
-$0.33
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $132.41M
- P/E ratio
- –
- Price to sales
- 2.20
- Price to book
- 8.88
- Dividend yield
- –
- Free cash flow yield
- -11.26%
Fundamentals
- Revenue
- $60.26M
- Net income
- $34.70M
- EPS, diluted
- -$0.33
- Free cash flow
- -$14.91M
- Book value per share
- $0.65
- Diluted shares
- 23M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$60.26M+3.3% YoY
Gross profit
$29.13M+5.8% YoY
Operating income
-$8.13M
Net income
$34.70M
EPS, diluted
-$0.33
Free cash flow
–
Reported periodTrailing twelve months